ArticleAngewandte Chemie (International ed. in English)2026
Photochemical Deracemization of Chromanes and its Application to the Synthesis of Enantiopure Bioactive Compounds.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Photochemical deracemization of α-chiral carboxamides mediated by inter- and intramolecular hydrogen bonding.Chemical science · 2026Article
- Stereoselective Epimerization of 1,3-Diols Using a Chiral Hydrogen Atom Abstraction Catalyst.Journal of the American Chemical Society · 2026Article
- Non-decarboxylative C-H Fluorination of Carboxylic Acids by Iridium Photocatalysis.Organic letters · 2026Article
- Photochemical Deracemization of Aza-1-isoindolinones: Critical Influence of Catalyst Substitution and the Nature of Its Resting State.Journal of the American Chemical Society · 2026Article
- Photochemical Deracemization of Chromanes and its Application to the Synthesis of Enantiopure Bioactive Compounds.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chromanes are frequently encountered as chiral structure elements in active pharmaceutical ingredients (APIs). We have now discovered an access to enantiopure chromanes, which employs a 1:1 mixture of their enantiomers (racemate) in a photochemical deracemization reaction (21 examples, 71%-90% yield, 80%-99% ee). A chiral photocatalyst (10 mol%) acts by selective hydrogen abstraction at one chromane enantiomer and establishes a photostationary state in which the other enantiomer prevails. A thiol additive (20 mol%) was found to improve the enantioselectivity of the process. The mechanism of the reaction was investigated by experimental and quantum-chemical studies. The oxygen atom of the chromane locks the rotation around the exocyclic C─C bond to the amide by forming an intramolecular hydrogen bond. Forward hydrogen atom transfer (HAT) occurs exclusively in one diastereomeric complex via a readily accessible transition state. Reasonable pathways for back HAT were identified which are in line with deuterium labeling experiments. The method was applied to the concise preparation of five chromane-containing drugs (Doxazosin, Fidarestat, Nebivolol, Repinotan, Sarizotan) as single enantiomers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.